1. Introduction {#sec1}
===============

Periprosthetic infection after total joint replacement is a devastating complication and occurs in up to 2% of primary joint replacements \[[@B1]--[@B5]\]. Treatment options include irrigation and debridement (I&D) with component retention \[[@B6]--[@B10]\], one-stage revision \[[@B11]--[@B13]\], or two-stage revision utilizing an antibiotic containing cement spacer \[[@B14]--[@B16]\].

Two-stage revision remains the golden standard treatment in the United States with infection-free survival rates of 80-100% \[[@B17]--[@B19]\]. An antibiotic containing cement spacer \[[@B14], [@B16]\] and intravenous antibiotics are routinely used for two-stage procedures. Zimmerli et al. \[[@B20]\] recommended two-stage revisions for patients with symptoms for more than 3 weeks or an index procedure performed more than 30 days ago.

Patients presenting with symptoms for less than 3 weeks or within 30 days of primary joint replacement without a sinus tract or radiographic evidence of component loosening can be considered for an I&D with retention of components in case of and a susceptible organism \[[@B21]\]. This approach is attractive because of its low-morbidity and cost effectiveness. However, failure rate of 7-79% has been reported and I&D is therefore in general considered less effective than two stage revision \[[@B6], [@B22]\].

There are much less clear recommendations for the treatment of recurrent infection following two stage revisions. Whiteside et al. \[[@B23]\] reported control of infection in 17 of 18 patients using aggressive I&D and intraarticular antibiotic infusion over 6 weeks after a failed two-stage treatment attempt.

The aim of the current study was to evaluate the clinical success rates of I&D after failed two-stage revision and to investigate the impact of the type of organism, patient age, general health condition (ASA), and comorbidities on treatment outcome.

2. Materials and Methods {#sec2}
========================

The current study is a retrospective chart review of 440 two-stage revisions for periprosthetic knee or hip infection performed at one tertiary referral center between 2002 and 2010.

Patient demographics including age, gender, BMI, health status (ASA), the timespan between I&D, and the prior failed two-stage procedure, as well as number and type of prior surgeries, were recorded. The American Society of Anesthesiologists (ASA) physical status classification score was used as a proxy variable for health status. The types of organisms and sensitivities were documented for all procedures. Quinolone resistant Gram-negative bacteria, rifampicin-resistant Staphylococcus, Enterococcus, and Candida were classified as "difficult to treat" (DTT) in accordance of Winkler et al. \[[@B24]\].

The diagnosis of infection prior to the index two-stage procedure was based on clinical signs, blood work (ESR, CRP), positive synovial fluid aspiration, and intraoperative cultures (following the state of art \[[@B25]\]). The index two-stage revisions included removal of implants and bone cement (Stage I). All patients received a static antibiotic containing cement spacer (knees) or an articulating spacer (hip) as well as systemic antibiotics based on organism sensitivity for 2 weeks intravenously and for an additional 4 weeks orally. The articulating hip spacers were performed as mould-spacers with an endoskeleton (67%) or as handmade spacers (33%) \[[@B26]\]. The knee spacers were performed as static, handmade spacers with an endoskeleton \[[@B27]\]. Two weeks after stopping the systemic antibiotics successful eradication was confirmed by repeat joint aspiration. If the aspiration was negative, CRP remained less than 2 g/dL and there was no sinus tract and a new implant was inserted (Stage II).

Reinfection occurred in 51 patients (11.6%) of 440 two-stage revisions. If a reinfection occurred (diagnosis of reinfection followed the consensus criteria by Zmistowski et al. \[[@B1]\]) within 30 days after two-stage revision or patients presented with an acute reinfection (symptoms for less than 3 weeks), aggressive, if necessary repeated I&D was performed. Nineteen of 51 patients fulfilled the inclusion criteria (32 patients were treated with a second two-stage procedure). The mean age at I&D after failed two-stage procedure was 67.3 years (range, 45.2 -- 84.5 years); there were 12 male and 7 female patients, 12 hips and 7 knees, 10 left and 9 right joints; the mean BMI was 29.6 kg/m^2^ (range, 21.5 to 36.4 kg/m^2^). Mean follow-up was 39 months (range, 24-90 months). At the time of each follow-up the absence of infection was evaluated by clinical criteria (no sinus tract, no swelling, no erythema, and no tenderness); if there was a reasonable suspicion of recurrent infection, an immediate work-up was done adhering to the guidelines by Parvizi et al. \[[@B25]\].

I&D was performed utilizing the preexisting incisions. After a thorough synovectomy and irrigation of the surgical site all removable components (hip: head and liner; knee: articular insert) were removed. Now the implant was cleaned and a through irrigation utilizing a minimum of 10 L of anti-infectious irrigation was performed. Finally the surgical field was covered with new drapes, new instruments were opened, and the surgeons and assistance were regloved and regowned. New mobile components were put in place and the wound was closed in layers in a usual way. If the soft tissues were not stable enough, 1-3 polyurethane sponges were inserted under the fascia or subcutaneously and were connected to a vacuum producing devise via tubes \[[@B28]\]; afterwards the wounds were still closed in layers under meticulous reconstruction and accurate adaptation of the tissue layers. A repeated I&D was performed 3-6 days later in a technique described by Kelm et al. \[[@B28]\]. The indication for a repetition of I&D was evidence of persistent microorganism intraoperatively, persisting drainage, no decrease of C-reactive protein within 6 days combined with clinical signs of persistent infection (overheat, reddening), or persisting sepsis.

All patients terminated the use of antibiotics two weeks after last surgery ("postoperative antibiotics", Tables [2](#tab2){ref-type="table"} and [4](#tab4){ref-type="table"}), and no suppression therapy was used.

Failure was defined as any additional surgery due to infection after hospital discharge. Only patients with a minimum follow-up of 24 months were included in the current study.

Descriptive statistics were calculated, including mean and frequency. Mann--Whitney test was used to determine differences between successes and failures. Chi-square tests were used to determine differences in proportions between dichotomous data.

All statistical analyses were performed using IBM SPSS Statistics software version 23 (Armonk, NY: IBM Corp.). A p-value of less than 0.05 was considered to be statistically significant.

3. Results {#sec3}
==========

Of 19 patients who underwent I&D for failed two-stage revision, 12 (63.2%) patients were infection-free after a minimum follow-up of 24 months (mean 39 months, range 24-90 months). A recurrent deep infection occurred in 6 patients (31.6%) and one patient died (5.3%). 8/11 hips (72.7%) and 4/7 (57.1%) knees were infection-free after the minimum follow-up.

Patients with successful (Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}) and failed treatment (Tables [3](#tab3){ref-type="table"} and [4](#tab4){ref-type="table"}) differed in regard to BMI (median, success group 31.5 kg/m^2^, reinfection group 25.5 kg/m^2^, p = 0.026), but there were no differences in age (p = 0.892), ASA grade (p = 0.989), and number of I&Ds (p = 0.243).

Causative organisms cultured at the time of I&D are reported in Tables [2](#tab2){ref-type="table"} and [4](#tab4){ref-type="table"}. "Difficult to treat" organisms occurred in 6 cases. Two polymicrobial infections were observed. No statistically significant difference was found concerning the distribution of DTT-organisms or polymicrobial infections between the successfully treated and failed group.

4. Discussion {#sec4}
=============

Periprosthetic infections are a devastating complication. Treatment options range from two-stage revision \[[@B22]\], one-stage exchange \[[@B11]\], or irrigation and debridement with retention of components \[[@B8]\]. There is an ongoing debate about the most appropriate treatment of an acute implant infection. While eradication rates are higher in two-stage procedures, quality of life and postoperative function might be better after one-stage and I&D procedures, respectively \[[@B29]--[@B31]\].

Eradication rates following revision of primary implant infections range from 61 to 100% for different treatment protocols \[[@B32], [@B29], [@B30]\]. However, literature on the treatment of recurrent infection is scarce. The current study reports the eradication rate utilizing I&D for recurrent periprosthetic infection within a time-window of 30 days or occurring symptoms less than 3 weeks in patients with failed two-stage revision for periprosthetic infection. In the present study similar eradication rates for an I&D (63.2%) after failed two-stage revision were shown compared to I&D in primary deep implant infection \[[@B6], [@B33], [@B34]\].

The current study has the following limitations. First, this is a retrospective study. Second, while the report is based on a large group of patients undergoing two-stage revision surgery cases, numbers in the current group of I&D for recurrent infection are too small to analyze the impact of the type of organism and its sensitivity on overall outcome of I&D. The numbers are also too small to make a differentiated analysis between hips and knees. Third, since patients did not undergo laboratory screening or recurrent aspiration, infections were assumed to be eradicated based on clinical criteria exclusively. Finally, the use of a polyurethane sponge with a vacuum-producing device during repeated I&Ds is not very well described in the literature. There are some reports using V.A.C-Instill with small patient-numbers, but only one study, in which also a deep sponge was placed and the wound was still closed anatomically \[[@B28]\] as in the current study. In our center the use of sponges with a vacuum system was left after 2010.

There are only a few papers that report on the treatment of failed treatment attempts of deep implant infections. There is no common sense of the best treatment after failed two-stage procedure. Stammers et al. \[[@B35]\] reported failure rates of 42% (8/19 knees) ([Table 5](#tab5){ref-type="table"}) for repeat two stage revision after failed initial two stage treatment.

There is a study using a decision tree analysis to determine the best treatment (quality of life) after failed revision for deep implant infection. Wu et al. \[[@B36]\] expected the highest QoL utilizing arthrodesis following a failed two-stage revision in patients with total knee replacement. In a clinical review Sherrell et al. \[[@B32]\] reported failure rates of 34% in two-stage revisions for patients who underwent I&D followed by two-stage revision due to persisting infection. The authors assumed that the failure rate of 34% is higher than in patients who undergo two-stage revision only ([Table 5](#tab5){ref-type="table"}).

Pagnano et al. \[[@B37]\] reported a reinfection rate of 18.7% (27/144 hips) after a first two-stage revision due to periprosthetic infection. The authors reported four treatment options after failed first two-stage revision: antibiotic suppression therapy, I&D, resection arthroplasty, or a second two-stage revision. Two of 3 patients did not need any further surgery after I&D and continuous oral suppressive antibiotic therapy. Sixteen patients were treated by resection arthroplasty after failed two-stage procedure. Three of these 16 patients (18.8%) had to undergo further surgeries for recurrence of infection. Eleven patients underwent a second two-stage revision, in 8 patients (72.7%), a recurrence of infection occurred and further surgeries were needed ([Table 5](#tab5){ref-type="table"}).

In the current study, if necessary, repeat I&D was performed (range, 1-10). Kelm et al. \[[@B28]\] reported an eradication rate of 92.9% using the above mentioned protocol. However, the literature is inconsistent and some studies \[[@B38]--[@B40]\] report a higher failure rate with repeated I&Ds.

In the current study Staphylococcus was the predominant bacterium (52.6%; coagulase-negative staphylococci 42.1%, Staphylococcus aureus 10.5%). This finding is in line with current literature \[[@B41], [@B42]\]. "Difficult to treat"-organisms (DTT) occurred in 6 patients. Winkler et al. \[[@B24]\] described rifampicin-resistant Staphylococci (Patient 1), quinolone-resistant gram-negative bacteria (Patient 18), Enterococci (Patient 5, 9, 12 and perished patient), and Candida as DTT-organisms. No differences concerning the success of I&D were observed in the present study according to the presence or absence of DTT-organisms. One polymicrobial infection (Patient 5 and 12) occurred in each group. It is not clarified yet if the classification of DTT-infections should include polymicrobial infections. Only 3 patients showed the same organism at the time of two-stage revision and I&D (2x MRSE: Patient 1 and 2; 1x Staph. aureus: Patient 7). Two patients (Patient 14 and 15) developed methicillin-resistance (Staph. Epidermidis). Zmistowski et al. \[[@B43]\] differentiate between recurrence of infection (same organism at the failed two-stage procedure and at the renewed flare-up infection) and "new" reinfection with a change of microorganism. They showed a persistent infection with the same organism in 31.5%. Haddad et al. \[[@B42]\] also reported a change of organism in reinfection in 3 of 4 (75%) patients and specified these patients as reinfected compared to the fourth patient with a "persisting infection". Kraay et al. \[[@B44]\] actually described a 100% "new" infection-rate after failed two-stage procedure (28 patients). Triantafyllopoulos et al. \[[@B45]\] also showed more "new" infections than persistent infections with the same microorganism. In the current study 84.2% of patients showed "new" infection. Due to the majority of "new" infections it can be concluded, as Zmistowski et al. \[[@B43]\] and Triantafyllopoulos et al. \[[@B45]\] do, that the host status with all possible comorbidities may be a major factor. The control and improvement of comorbidities cannot be overstated as the mentioned studies describe a high vulnerability of the host for a "new" infection with a high Charlson Comorbidity Index. For patients with a high Charlson Comorbidity Index as a vulnerable host and an increased risk of perioperative complications the concept of I&D (defined as an acute reinfection within above mentioned time window) is a feasible option of treatment. On the other hand Zmistowski et al. \[[@B43]\] showed the only independent predictor of persistent periprosthetic joint infection was a primary infection with Staphylococcus in general, and MRSA in particular. These numbers can be shown in the current study as well as all three persistent infections occurred in patients with a Staphylococcus-infection. At the current study all persistent infections (n = 3; same microorganism within the failed two-stage procedure and the reinfection) are in the "infection free" group after I&D. It is unclear why the success rate in persistent infections was 100%. Three reasons of this circumstance could be as follows: first, the basis of the mature biofilm (prosthesis) was removed during the two-stage procedure and it might be that the revival of a mature biofilm at the new prosthesis was sufficiently stopped by a timely I&D. Second, the numbers of patients are too small. Third, the follow-up period is too short. The antibiotic therapy used in the current study follows the guidelines by Osmon et al. \[[@B20]\].

In summary, the failure rate of I&D for acute recurrence of infection (within 30 days of symptoms or 3 weeks of two stage procedure) following failed two-stage treatment was 31.6% in the present study. Therefore the concept of I&D after failed two-stage procedure might be an option in acute reinfections more than in persistent infections. The success rate is comparable to I&D for infection of a primary joint replacement. Careful indication (see criteria), meticulous surgical debridement, and close cooperation between the microbiologist, infectious disease doctor, and surgeon are recommended.
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###### 

Successful cases and demographics.

  **Patient**   **Age (years)**   **Gender**   **Joint**   **Side**   **ASA grade**   **Follow up (months)**   **BMI**   **Comorbidities**
  ------------- ----------------- ------------ ----------- ---------- --------------- ------------------------ --------- ------------------------------------------------------------------
  1             73.5              male         Hip         R          3               33                       34.2      HTN, A
                                                                                                                         
  2             46.5              male         Hip         R          3               34                       32.1      HTN, SM, A
                                                                                                                         
  3             68.3              male         Hip         L          3               28                       30.9      HTN, CKF
                                                                                                                         
  7             74.4              female       Hip         L          3               63                       36.4      HTN, post enterovesical fistula
                                                                                                                         
  8             63.2              male         Hip         L          2               77                       21.5      SM, DM
                                                                                                                         
  9             64.3              female       Hip         R          2               24                       35.4      HTN, CHF
                                                                                                                         
  11            52.9              female       Hip         L          2               90                       34.3      \-
                                                                                                                         
  12            75.9              female       Knee        R          3               24                       32.8      HTN, absolute arrhythmia in atrial fibrillation
                                                                                                                         
  13            45.2              male         Knee        R          2               25                       29.3      Post ORIF femur
                                                                                                                         
  14            76.2              male         Knee        R          3               30                       29.8      HTN, CHD, CHF, CKF, absolute arrhythmia in atrial fibrillation
                                                                                                                         
  18            84.5              male         Hip         L          4               28                       24.2      HTN, CHD, CKD, post apoplexy, morbus parkinson, chronic cystitis
                                                                                                                         
  19            67.4              female       Knee        R          3               27                       29.7      Bipolar psychosis, lumbar spinal syndrome

DM = diabetes mellitus, HTN = arterial hypertension, CHD = coronary heart disease, CHF = chronic heart failure, CKF = chronic kidney failure, COPD = chronic obstructive pulmonary disease, SM = smoker, A = alcohol (\> 20 g/d), DA = drug abuse

###### 

Successful cases with organism type, resistogram, and antibiotics; failed two-stage revision was done at a tertiary referral center; prior surgeries (column 2) were done in external clinics.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient   Revision surgeries prior to failed two-stage revision   Organism type: failed two-stage revision   Antibiotics preoperative   Number of surgeries (I&D)   Organism type: I&D             Antibiotics postoperativ   Resistant\
                                                                                                                                                                                                                                against
  --------- ------------------------------------------------------- ------------------------------------------ -------------------------- --------------------------- ------------------------------ -------------------------- ------------------------
  1         Two-stage revision                                      MRSE                                       Va, Ti, Ri                 1                           MRSE                           Va, Ti, Ri                 Ox, Ri, Ci, Ge, Cl, Im

                                                                                                                                                                                                                                

  2         \-                                                      MRSE                                       Le, Ri                     7                           MRSE                           Le, Va, Ri                 Ox, Ci, Ge, Cl

                                                                                                                                                                                                                                

  3         Revision due to bursitis intertrochanterica             Staph. capitis                             Le, Ri                     1                           Strepto. intermedius           Le, Ri                     Cl

                                                                                                                                                                                                                                

  7         \-                                                      Staph. aureus                              \-                         8                           Staph. aureus                  Le, Fl, Ri                 \-

                                                                                                                                                                                                                                

  8         Bursectomy, Exchange of cup                                                                        Le, Ri                     7                           MRSE                           Va, Cl, Ri                 Ox, Ce, Im

                                                                                                                                                                                                                                

  9         Soft tissue revision                                    Strepto. agalactiae                        Fl, Ri                     1                           Enterococcus faecalis          Fl, Am, Ri                 Ge, Cl, Ce

                                                                                                                                                                                                                                

  11        \-                                                                                                 Le, Ri                     2                           Staph. aureus                  Le, Ri                     \-

                                                                                                                                                                                                                                

  12        Two-stage revision                                                                                 Le, Ri                     5                           \(1\) Enterococcus faecalis\   Le, Amp, Ri                \(1\) Ge, Cl\
                                                                                                                                                                      (2) Peptostrepto. magnus                                  (2) -

                                                                                                                                                                                                                                

  13        ORIF (tibiaplateau fracture)                            MRSE                                       \-                         6                           Escherichia coli               Le, Ce, Ri                 \-

                                                                                                                                                                                                                                

  14        \-                                                      Staph. epi                                 Le, Ri                     11                          MRSE                           Va, Ri                     Ox, Ge, Cl, Ce, Va, Im

                                                                                                                                                                                                                                

  18        Two-stage revision                                      Staph. aureus                              \-                         7                           Escherichia coli               Me, Ri                     Le, Ci,

                                                                                                                                                                                                                                

  19        3x two-stage revision                                   Strept. simulans                           Le, Ri                     5                           Escherichia coli               Le, Ri                     \-
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MRSE = methicillin-resistant staphylococcus epidermidis, Ox = oxacillin, Ri = rifampicin, Le = levofloxacin, Ci = ciprofloxacin, To = tobramycin, Fl = flucloxacillin, Ge = gentamicin, Cl = clindamycin, Ce = cefuroxime, Va, = vancomycin, Li = linezolid, Im = imipenem, Ti = tigecycline, Am = amoxicillin, Amp = ampicillin, Mo = moxifloxacin, Me = meropenem

###### 

Failed cases and demographics.

  **Patient**   **Age (years)**   **Gender**   **Joint**   **Side**   **ASA grade**   **Follow up (months)**   **BMI**   **Comorbidities**
  ------------- ----------------- ------------ ----------- ---------- --------------- ------------------------ --------- ---------------------------------------------------------------------------------------------------
  5             76.6              female       Hip         R          3               55                       23.5      Post cerebellar infarction, osteoporosis, post humerus-fracture
                                                                                                                         
  6             70.8              male         Hip         L          3               29                       27.8      DM, HTN, CHD, CHF, CKF, post quadruple coronary artery bypass, both sided carotid artery stenosis
                                                                                                                         
  10            62.4              male         Hip         R          2               29                       26.3      SM, A, post transient ischemic attack
                                                                                                                         
  15            61.9              male         Knee        L          2               49                       29.8      HTN, post phlebothrombosis
                                                                                                                         
  16            78.5              female       Knee        L          3               35                       23.5      \-
                                                                                                                         
  17            62.1              male         Knee        L          4               24                       24.7      DM, HTN, CHD (bio heart valve, pacemaker), CKD (IgA nephropathy), A, post phlebothrombosis

DM = diabetes mellitus, HTN = arterial hypertension, CHD = coronary heart disease, CHF = chronic heart failure, CKF = chronic kidney failure, COPD = chronic obstructive pulmonary disease, SM = smoker, A = alcohol (\> 20 g/d), DA = drug abuse

###### 

Failed cases.

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Patient                     Revision surgeries prior to failed two-stage revision                         Organism type: failed two-stage revision   Antibiotics preoperative   Number of surgeries (I&D)   Organism type: I&D     Antibiotics postoperative   Resistant\
                                                                                                                                                                                                                                                                 against
  --------------------------- ----------------------------------------------------------------------------- ------------------------------------------ -------------------------- --------------------------- ---------------------- --------------------------- --------------------
  5                           Inlay exchange (multiple dislocations), multiple surgeries due to infection   \(1\) Staph. aureus                        Le, Ri                     5                           \(1\) MRSE             Va, Ri                      \(1\) Ox, Ci, Cl

  \(2\) Staph. haemolyticus   \(2\) Enterococcus faecium                                                                                                                                                                                                         

  \(2\) Ci, Ge, Cl                                                                                                                                                                                                                                               

                                                                                                                                                                                                                                                                 

  6                           Exchange of cup                                                               MRSE                                       Cl, Ri                     5                           Enterobacter cloacae   Le, Ri                      \-

                                                                                                                                                                                                                                                                 

  10                          Exchange of cup (3x)                                                          Staph. epidermidis                         \-                         2                           \-                     Le, Ri                      \-

                                                                                                                                                                                                                                                                 

  15                          Arthroscopy with synovectomie                                                 Staph. epidermidis                         Le, Ri                     1                           MRSE                   Va                          Ox, Ge, Cl, Ce, Im

                                                                                                                                                                                                                                                                 

  16                          \-                                                                            Candida albicans                           \-                         3                           MRSE                   Cl                          Ox, Ge, Ce, Im

                                                                                                                                                                                                                                                                 

  17                          2x two-stage revision, 1x tibial exchange                                     Enterobacter cloacae                       Me                         7                           MRSE                   Va, Mo, Ri                  Ox, Ge, Ce, Im
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

MRSE = methicillin-resistant staphylococcus epidermidis, Ox = oxacillin, Ri = rifampicin, Le = levofloxacin, Ci = ciprofloxacin, To = tobramycin, Fl = flucloxacillin, Ge = gentamicin, Cl = clindamycin, Ce = cefuroxime, Va, = vancomycin, Li = linezolid, Im = imipenem, Ti = tigecycline, Am = amoxicillin, Amp = ampicillin, Mo = moxifloxacin, Me = meropenem

###### 

Failure rates after failed revisions due to periprosthetic infection.

  **Author**                   **First Revision**   **Second Revision**      **Failure-rate**
  ---------------------------- -------------------- ------------------------ ------------------
  Stammers et al. \[[@B35]\]   Two-stage revision   Two-stage revision       42% (8/19)
                                                                             
  Sherrell et al. \[[@B32]\]   I&D                  Two-stage revision       34% (28/83)
                                                                             
  Pagnano et al. \[[@B37]\]    Two-stage revision   Resection arthroplasty   19% (3/16)
  Two-stage revision           Two-stage revision   73% (8/11)               
                                                                             
  Current study                Two-stage revision   I&D                      32% (6/19)
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